That's more than double China's rate and six times the USA's. Most sites already have SOPs, QMS, and training records - so why do the observations continue?
FDA warning letter trends show a striking gap: 60% of warning letters issued to Indian pharmaceutical manufacturers cite Data Integrity failures, compared with 21% for China and 10% for the USA. The pattern holds even though most organizations already have the standard controls in place.
This carousel walks through what's actually driving that gap - and why it isn't a documentation, training, or systems problem.
60% of FDA warning letters issued to Indian pharmaceutical manufacturers cite Data Integrity failures.
How does that compare? India: 60%. China: 21%. USA: 10%.
Most organizations already have SOPs, Quality Management Systems, and training records - yet the observations continue.
The difference isn't just documentation, training, or systems. It's whether employees can recognize risks, make the right decisions, and consistently apply GMP requirements.
Training records demonstrate compliance. Workforce capability demonstrates execution. Inspection readiness depends on both.
Data integrity failures aren't usually about people trying to hide something - they're usually about people who were trained but never verified as capable of applying the SOP correctly, every time, under real production pressure.
